Treatment of metastatic carcinoid tumour with recombinant interferon alfa
| Autor: | E. Kumpulainen, Heikki Joensuu, Pentti Gröhn |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Urinary system Alpha interferon Carcinoid Tumor Gastroenterology Metastasis Internal medicine medicine Humans Interferon alfa Aged Malignant Carcinoid Syndrome business.industry Hydroxyindoleacetic Acid Middle Aged medicine.disease Symptomatic relief Recombinant Proteins Surgery nervous system Oncology Interferon Type I Female business Interferon type I Carcinoid syndrome Follow-Up Studies medicine.drug |
| Zdroj: | European Journal of Cancer. 28:1650-1653 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/0959-8049(92)90061-6 |
| Popis: | 14 patients with metastatic carcinoid tumour were treated with recombinant interferon alfa 6-30 x 10(6) IU weekly for 3-25 (median 6.5) months. A decrease in the 24-h urinary 5-hydroxyindoleacetic acid (5-HIAA) level to less than 50% of the pretreatment value was observed in 5 of the 10 cases with an elevated urinary 5-HIAA level. In 4 of the 5 remaining patients, the 5-HIAA level decreased 30-50% from the pretreatment value. 5 of the 9 evaluable patients with carcinoid syndrome experienced symptomatic relief, but none became symptom-free. Severe toxicity was not observed. The median time to progression was 4.5 months, and, in patients with a greater than 50% decrease in 24-h urinary-5-HIAA, it was 17 months. Objective regression in tumour size could not be demonstrated in any of the patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|